Drug intelligence / Profile preview

sertraline + omega-3

Development stage
Unknown
Lead developer
Pfizer
Modality
Small Molecules
Administration
Oral
01

Overview

Sertraline + omega-3 is a combination therapy involving the selective serotonin reuptake inhibitor (SSRI) sertraline and omega-3 fatty acids, typically eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). Sertraline acts by inhibiting the reuptake of serotonin in the brain, thereby increasing its availability and improving mood. Omega-3 fatty acids are thought to have anti-inflammatory properties and may modulate neurotransmitter function, including interactions with serotonergic pathways. This combination has been studied primarily for major depressive disorder, especially in patients with comorbid coronary heart disease or elevated cardiovascular risk factors. Clinical trials have generally not shown a significant benefit of adding omega-3 supplementation to sertraline over sertraline alone for depression outcomes[1][2][4][5]. However, some studies suggest potential benefits on certain secondary measures such as social functioning or cardiovascular risk factors[1][5].

Other names
fish oil + sertralineomega-3 fatty acids + sertralineEPA/DHA + sertraline
02

Targets

SERT (Sodium-dependent serotonin transporter)NET (Norepinephrine Transporter)DAT (Dopamine plasma membrane transport protein)

Beyond the preview

Go deeper on sertraline + omega-3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on sertraline + omega-3.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call